PET-CT scans for pancreatic cancer patients eliminates additional surgery

A recent guideline from the National Institute for Health and Care Excellence (NICE) in the United Kingdom recommends PET-CT scans should be used to more quickly and accurately diagnosis and manage pancreatic cancer, resulting in a 20 percent reduction in surgery to remove the cancer.  

According to a NICE press release, this recommendation will ultimately mean that pancreatic cancer patients whose cancer has spread and is "inoperable" will not need to undergo additional surgery. Additionally, this will also limit the damaging side effects of chemotherapy many pancreatic patients endure for treatment.

"The PET-CT scan could have a significant impact on the treatment of patients with pancreatic cancer," said Mark Baker, director of the center for guidelines at NICE. "It will mean that the staging process is more effective so that patients stand a better chance of getting the right treatment, at the right time."

According to NICE, pancreatic cancer is the fifth leading cause of cancer death in the U.K., with more than 9,500 cases diagnosed every year.

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.